Phase 1 Open-Label Multicenter, Dose-Escalating, Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of SNS-314, a Novel Aurora Kinase Inhibitor, Administered to Patients With Advanced Solid Tumors

Inclusion Criteria:

- Advanced solid tumor and that is measurable by a scan

Exclusion Criteria:

- Uncontrolled or untreated central nervous system metastases

- Cerebrovascular accident/transient ischemic attack up to 6 months before Cycle 1 Day
1

- Any of the following cardiac conditions:

- History of myocardial infarction, acute coronary syndromes up to 12 weeks before
Cycle 1 Day 1

- Class III or IV heart failure up to 6 months before Cycle 1 Day 1

- Baseline heart rate corrected QT interval (QTc)> 450 msec

- History of ventricular arrhythmias up to 6 months before Cycle 1 Day 1

- Use of medications that prolong the QTc interval and are associated with Torsades de
Pointe (TdP)

- Previous cancer treatment up to 21 days before first dose

- Any investigational therapy up to 28 days before Cycle 1 Day 1

- Known allergy to cyclodextrins

Please note: There are additional inclusion/exclusion criteria for this study. Please
contact the study center for additional information and to determine if all study criteria
are met.